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a b s t r a c t
Typhoid fever is a public health problem, especially among young children in developing countries. To
address this need, a glycoconjugate vaccine Vi-CRM197, composed of the polysaccharide antigen Vi cova-
lently conjugated to the non-toxic mutant of diphtheria toxin CRM197, is under development. Here, we
assessed the antibody and cellular responses, both local and systemic, following subcutaneous injection
of Vi-CRM197. The glycoconjugate elicited Vi-speciﬁc serum IgG titers signiﬁcantly higher than uncon-
jugated Vi, with prevalence of IgG1 that persisted for at least 60 days after immunization. Vi-speciﬁceywords:
i antigen
RM197
onjugate vaccine
mmunogenicity
IgG, but not IgA, were present in intestinal washes. Lymphocytes proliferation after restimulation with
Vi-CRM197 was observed in spleen and mesenteric lymph nodes. These data conﬁrm the immunogenic-
ity of Vi-CRM197 and demonstrate that the vaccine-speciﬁc antibody and cellular immune responses
are present also in the intestinal tract, thus strengthening the suitability of Vi-CRM197 as a promising
t Salmalmonella Typhi
ocal immune response
candidate vaccine agains
. Introduction
Typhoid fever, an illness caused by the human adapted
almonella enterica serovar Typhi (S. Typhi), occurs predominantly
mong young children in resource poor settings [1]. Transmission
ccurs through contaminated food and water; human infection
nvolves bacterial penetration of the intestinal epithelial barrier
nd migration via the blood stream to the reticuloendothelial cells
f liver, spleen and other lymphoid tissues, where bacteria can
eplicate [2]. The virulence capsule (Vi) is a major protective anti-
en against typhoid fever and therefore a main target of vaccines.
he Novartis Vaccines Institute for Global Health (NVGH) is devel-
ping the Vi-CRM197 glycoconjugate vaccine for use in endemic
ettings [3–6]. This vaccine is currently in phase 2 clinical trials
n south Asia [7]. Citrobacter Vi has been used as the vaccine anti-
en due to advantages in terms of safety and manufacturing costs
6,8]. The carrier protein CRM197 is the well characterized diphthe-
ia toxin mutant and an approved carrier licensed for childhood
accines [9]. Preclinical immunogenicity, toxicology and bacterial
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challenge studies previously conducted using Vi-CRM197 provided
encouraging results andwere the basis to start human clinical trials
[3,4,6].
In the present work, we expand the previous preclinical
immunogenicity data of Vi-CRM197. Local and systemic antibody
responses to the glycoconjugate, as well as the T-cell response in
the spleen and in mesenteric lymph nodes, were characterized and
compared with unconjugated Vi responses.
2. Materials and methods
2.1. Antigens
Vi and Vi-CRM197 were prepared as previously described [3–6].
Vi was puriﬁed from a member of the Citrobacter freundii com-
plex [6]. The Vi contained <0.1% nucleic acid, <0.5% protein and
<10UI/g endotoxin. It had an O-acetylation level >90% and a
Kd=0.35. Vi-CRM197 had a Vi/CRM197 ratio of 0.91 (wt/wt) and
a Kd=0.109. Its O-acetylation level was >90% and <0.5UI/g
endotoxin. CRM197 was obtained from Novartis Vaccines and Diag-
nostics (Siena, Italy).
2.2. Immunization and sample collectionGroups of six-week old BALB/c mice (Charles River, Lecco,
Italy) were immunized subcutaneously with Vi-CRM197 (12 mice),
Vi (8 mice), CRM197 (8 mice) or PBS (8 mice). A dose of 1g/mouse
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boosting (day 24) showed a predominance of IgG1 in mice
immunized with Vi-CRM197 (P < 0.001 versus other subclasses;
Table S3) that were signiﬁcantly higher than those observed
in mice immunized with Vi antigen alone (P ≤ 0.001; Fig. 1C).
Fig. 1. Vi-speciﬁc serum antibody response. BALB/c mice were subcutaneously
immunized  with Vi-CRM197, unconjugated Vi, CRM197 or PBS at days 1 and 14
(arrows).  (A and B) Vi-speciﬁc IgM (A) and IgG (B) responses were assessed by ELISA
on individual serum samples at days 0, 13, 24, 42 and 60 following the ﬁrst immu-
nization.  Values are reported as GMT  ± SEM. One-way ANOVA and Tukey’s post test
for multiple comparisons were performed for all groups at all time points and P
values are reported in Tables S1 and S2. (C) Vi-speciﬁc IgG1, IgG2a, IgG2b and IgG3112 F. Fiorino et al. / Vac
f Vi (alone or conjugated to CRM197) or CRM197 alone was deliv-
red at days 1 and 14. The immunization dose was selected from
ose-ranging studies [4]. Half of the mice per group were sacri-
ced ten days after the second immunization and the rest on day
0. Blood samples were taken on days 0, 13, 24, 42 and 60. Intesti-
al washes were performed at days 24 or 60 [10] and stored at
80 ◦C after addition of protease inhibitors [11]. Erythrocyte con-
amination in intestinal washes, estimated to be 0.015 ± 0.002%
mean ± SD, by comparing erythrocyte number in intestinal washes
ith that of blood), was too low to account for the observed intesti-
al antibody response. Spleen and mesenteric lymph nodes were
ollected at sacriﬁce from each animal [12]. Animal studies were
pproved by the institutional Animal Ethical Committee and by the
ompetent national authorities.
.3.  ELISA
Serum Vi-speciﬁc IgG, IgG subclasses, IgA, and IgM were deter-
ined by ELISA, as described [4]. Antibody titers were expressed as
he reciprocal of the highest dilution with an optical density value
0.2 after background subtraction.
Intestinal Vi-speciﬁc IgG and IgA were assessed as previously
escribed [10]. As the concentration of IgG and IgA in intestinal
ashes is variable, the amount of Vi-speciﬁc immunoglobulins was
ormalized to the total antibody concentration in each sample [10].
.4. T-cell proliferation assay and IFN- ELISPOT
Proliferation of pooled splenocytes or lymphocytes from mesen-
eric lymph nodes was determined as described [12]. Cells were
timulated with 10 g/ml Vi-CRM197, Vi polysaccharide or medium
lone. Results were expressed as stimulation index (S.I.), calculated
s the ratio between the mean counts per minute of stimulated
ersus unstimulated cells tested in triplicate. IFN- ELISPOT assay
as conducted as previously described [12].
.5. Statistical analysis
Sera  and intestinal washes were tested individually and values
ere expressed as mean ± standard error of the mean (SEM). Statis-
ical differences between antibody production among groups were
ssessed using one-way analysis of variance (ANOVA) and Tukey’s
ost test for multiple comparisons. Two-tailed Student’s t-test was
sed for analyzing differences in antibody titers at different time
oints and for analyzing IgG subclasses between Vi-CRM197 and Vi
mmunized mice. The correlation between the antibody concen-
ration in sera and intestinal washes in each animal was performed
alculating the Pearson’s correlation coefﬁcient r. The lymphopro-
iferative response between groups was analyzed using one-way
NOVA and Tukey’s post test. Statistical signiﬁcance was deﬁned
s P ≤ 0.05. Graphpad 4.0 software was used for analysis.
. Results and discussion
.1.  Systemic antibody response
Vi-speciﬁc serum antibodies were assessed in mice subcuta-
eously immunized with Vi-CRM197, unconjugated Vi, free CRM197
r PBS. Two weeks after priming (day 13), both Vi-CRM197 and
i immunized mice developed a signiﬁcant serum Vi-speciﬁc IgM
esponse with a geometric mean titer [GMT] of 1280 and 425
espectively (P < 0.001 versus PBS immunized mice; Fig. 1A and
able S1). IgM titers induced by the glycoconjugate were signiﬁ-
antly higher than those observed in Vi immunized mice (P < 0.01)
Fig. 1A and Table S1). After boosting, Vi-speciﬁc IgM signiﬁcantly (2012) 6111– 6114
decreased  (P < 0.05) while IgG signiﬁcantly increased in Vi-CRM197-
immunized mice (GMT of 1689 after priming [day 13] and of 4560
after boosting [day 24], P < 0.01) and persisted until day 60 with
titers signiﬁcantly higher compared to mice immunized with Vi or
CRM197 alone (P < 0.001; Fig. 1B and Table S2). In Vi-immunized
mice the IgG response did not signiﬁcantly increase after boosting,
and persisted up to day 60 with a GMT  of about 256 (P < 0.001 versus
PBS and CRM197 groups; Fig. 1B and Table S2). The IgG response
detected in mice immunized with Vi-CRM197 was  about 8 times
higher than that induced by unconjugated polysaccharide Vi after
the primary immunization and about 18 times higher after boost-
ing. These data demonstrate that the glycoconjugate was more
efﬁcient in stimulating antibody isotype switching.
The analysis of Vi-speciﬁc serum IgG subclasses 10 days aftersubclasses were assessed in individual sera collected at day 24 following immu-
nization.  Values are reported as GMT ± SEM. One-way ANOVA and Tukey’s post
test for multiple comparisons were performed for analyzing differences among IgG
subclasses within Vi-CRM197 or Vi immunized mice and P values are reported in
Table S3.
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Fig. 3. Proliferative response of lymphocytes. Lymphocytes from spleen (A) and
mesenteric lymph nodes (B) were collected at day 60 after immunization with Vi-
CRM197, unconjugated Vi, CRM197 or PBS, and restimulated in vitro with Vi-CRM197.
Proliferation  of lymphocytes was determined by measuring incorporation of [3H]F. Fiorino et al. / Vac
hese data corroborate the IgG subclass switch observed with
ther polysaccharides, such as pneumococcal and meninogococcal
olysaccharides and their respective conjugate vaccines [13–15].
o signiﬁcant levels of serum Vi-speciﬁc IgA were detected in
ny group. Mice immunized with Vi-CRM197 developed a CRM197-
peciﬁc serum IgG response with a subclass distribution similar to
hat observed for anti-Vi IgG (data not shown).
This work therefore shows that boosting with Vi-CRM197
nduces a signiﬁcant increase of serum IgG typical of secondary
ntibody response to T-dependent antigens, and a dominance of the
gG1 subclass. Increased serum IgG has been indeed documented
o be the correlate of protection for many microorganisms, includ-
ng enteric pathogens such as Salmonella and Shigella [16]. Elevated
erum IgG to the Vi antigen has been shown to confer protection
gainst typhoid fever in ﬁeld trials with the Vi polysaccharide and
ith the Vi-rEPA conjugate vaccine [17,18]. The role of Vi-speciﬁc
erum IgG to reduce bacterial load following challenge with a Vi-
ositive S. Typhimurium strain in a mouse model has also been
emonstrated [4,19]. Interestingly, it has been recently published
hat unconjugated Vi polysaccharide is not only a poor immuno-
en, but it suppresses the immune response to a subsequent boost
ith the conjugate vaccine [20]. On the contrary, no suppression
as been observed when priming with conjugate and boosting with
ither conjugate or unconjugated Vi [20].
.2. Gut antibody response
The  local Vi-speciﬁc antibody response was  analyzed in the
ntestinal tract. Signiﬁcant levels of Vi-speciﬁc IgG were detected
n intestinal washes from Vi-CRM197 immunized mice with a
ean concentration of 9.3 g/mg of total IgG 10 days following
he second immunization (P < 0.05 versus all groups), while no
ntestinal response was  detected in mice immunized with Vi or
RM197 (Fig. 2A). Signiﬁcant correlation was observed between
ig. 2. Vi-speciﬁc IgG and IgA in intestinal washes. Vi-speciﬁc IgG (A) and IgA (B)
n intestinal washes were assessed 24 and 60 days following immunization with
i-CRM197, unconjugated Vi, CRM197 or PBS. Vi-speciﬁc antibodies were normalized
o  the total amount of IgG or IgA assessed in each sample. Values are expressed
s  g of Vi-speciﬁc IgG or IgA per mg  of the respective total IgG or IgA detected
n  each individual sample. Results are reported as mean ± SEM. One-way ANOVA
nd  Tukey’s post test for multiple comparisons were used for comparing antibody
esponse  in different groups at each time point (day 24 and day 60). * P < 0.05.
thymidine. Samples from 6 mice (Vi-CRM197 group) and 4 mice (Vi, CRM197 and PBS
groups)  were pooled and tested in triplicate. Results are expressed as S.I. of stim-
ulated versus untreated cells. Bars represent mean S.I. ± SEM of triplicate samples.
One-way  ANOVA and Tukey’s post test for multiple comparisons was  performed for
all groups; *P < 0.05 and ***P < 0.001 versus PBS immunized mice; ##P < 0.01 versus
Vi  immunized mice.
Vi-speciﬁc IgG detected in serum and intestinal washes in each
mouse immunized with Vi-CRM197 (r = 0.87, P = 0.0002), suggest-
ing that intestinal IgG may  be derived from passive diffusion
from blood. Notably, Vi-speciﬁc IgA was not observed in intesti-
nal washes from any group (Fig. 2B). These observations indicate
the potential of parenteral vaccination to induce immunity in the
intestinal tract, a feature generally associated with mucosal immu-
nization routes.
3.3.  Cellular immune response
Cellular  proliferation was observed in splenocytes of Vi-CRM197
immunized mice, with a S.I. of 10 (P < 0.05 versus PBS group) while
lower proliferation was  observed in mice immunized with Vi anti-
gen alone (Fig. 3A). The CRM197 carrier component was  necessary
for the in vitro lymphoproliferative response, as conﬁrmed by
the absence of cell proliferation after restimulation with uncon-
jugated Vi (data not shown). Therefore, Vi-CRM197 is efﬁcient in
stimulating a T-cell response that in turn augments Vi-speciﬁc
B cells to produce antibodies. Restimulated lymphocytes from
mesenteric lymph nodes of mice immunized with Vi-CRM197 also
showed a robust proliferation (S.I. 23, P < 0.001 versus PBS group,
P < 0.01 versus Vi-immunized mice; Fig. 3B) and IFN- production
(25 SFU/106 lymphocytes versus 0.2 SFU/106 lymphocytes in PBS
control group, data not shown). These data suggest that antigen-
speciﬁc T cells stimulated by parenteral immunization recirculate
and migrate into lymph nodes draining the intestine. Recently, we
have also demonstrated dissemination of antigen-speciﬁc activated
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 cells to distal non-draining lymph nodes, including mesenteric
ymph nodes, following nasal immunization [21].
.  Conclusions
The local and systemic antibody and cellular responses in mice
mmunized with the glycoconjugate Vi-CRM197 has been charac-
erized and compared with the responses induced by unconjugated
i. Our data showed that in mice Vi-CRM197 elicited: (i) signiﬁcant
ncrease of Vi-speciﬁc serum IgG; (ii) an increase of IgG/IgM ratio
fter boosting; (iii) a prevalence of IgG1 in serum; (iv) Vi-speciﬁc
gG antibodies in intestinal washes; and (v) lymphoproliferative
esponses  in both spleen and mesenteric lymph nodes and IFN-
 production by lymphocytes from mesenteric lymph nodes after
estimulation with Vi-CRM197.
This work documents that the glycoconjugate Vi-CRM197 gener-
tes a stronger and qualitatively different serum antibody response
ompared to the unconjugated Vi and demonstrates that vaccine-
peciﬁc antibody and cellular immune responses are present also
n the intestinal tract. These data further support the suitability of
i-CRM197 as promising candidate vaccine against S. Typhi.
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